A detailed history of Kestra Advisory Services, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Kestra Advisory Services, LLC holds 5,183 shares of PTGX stock, worth $210,688. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,183
Holding current value
$210,688
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$33.72 - $47.33 $174,770 - $245,311
5,183 New
5,183 $232,000
Q1 2022

Apr 26, 2022

SELL
$23.34 - $36.08 $182,822 - $282,614
-7,833 Closed
0 $0
Q4 2021

Jan 20, 2022

BUY
$17.63 - $37.1 $138,095 - $290,604
7,833 New
7,833 $267,000
Q3 2021

Oct 19, 2021

SELL
$12.95 - $49.69 $180,510 - $692,628
-13,939 Closed
0 $0
Q2 2021

Jul 28, 2021

BUY
$25.57 - $44.88 $7,926 - $13,912
310 Added 2.27%
13,939 $625,000
Q1 2021

May 10, 2021

BUY
$19.02 - $31.15 $259,223 - $424,543
13,629 New
13,629 $352,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Kestra Advisory Services, LLC Portfolio

Follow Kestra Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kestra Advisory Services, LLC with notifications on news.